Phaseline

Targets › FLG

FLG (Filaggrin): drug programs, companies and trials

1 program from 1 company in 5 trials: 3 Phase 3, 2 Phase 2; Immunology; next expected readout Dec 2026.

Aggregates keratin intermediate filaments and promotes disulfide-bond formation among the intermediate filaments during terminal differentiation of mammalian epidermis. (UniProt, P20930)

Open in Phaseline: the race on FLG, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Celldex TherapeuticsBarzolvolimab
Anti-filaggrin monoclonal antibody
FLGPhase 3Chronic Spontaneous Urticaria; Chronic Inducible Urticaria; Atopic Dermatitis; Prurigo NodularisDec 2026

Conditions

Chronic Spontaneous Urticaria (2) Chronic Inducible Urticaria (1) Atopic Dermatitis (1) Prurigo Nodularis (1)

Modalities

antibody (1)

Companies

Celldex Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.